Bio Roundup: IDO Fallout, Express Scripts Dumps Amgen, Isaly Out & More
Xconomy
MAY 4, 2018
Here’s a case study of how fast things can change in biopharma. For a few years, a type of cancer drug called an IDO inhibitor was all the rage, a promising path to expanding the reach of immunotherapy. Major drug makers were dealing, too. Through acquisitions and alliances, they rolled out a spate of large-scale combination trials.
52 
Let's personalize your content